Non-Melanoma Skin Cancer Aggravation in Polycythemia Vera: Triggered by Ruxolitinib and Silenced With an IFN/Cemiplimab

相似書籍

• Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis
  由: Stine Ulrik Mikkelsen, et al.
  出版: (2018-08-01)
• Current Issues of Targeted Therapy of Polycythemia Vera
  由: Anait Levonovna Melikyan, et al.
  出版: (2021-07-01)
• Approaches to the Treatment of Patients with Myelofibrosis and Polycythemia Vera with Constitutional Symptoms in Real-World Clinical Practice in the Russian Federation: Intermediate Results of a Multi-Center Observational Prospective Clinical Study
  由: Anait Levonovna Melikyan, et al.
  出版: (2023-03-01)
• Ruxolitinib and Hydroxycarbamide Are the Most Efficient Drugs to Reduce Aquagenic Pruritus Intensity in a Real‐Word Cohort of Patients With Myeloproliferative Neoplasms
  由: Christelle Le Gall‐Ianotto, et al.
  出版: (2025-12-01)
• Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project
  由: Srdan Verstovsek, et al.
  出版: (2023-07-01)